Head-To-Head Comparison: CytomX Therapeutics (NASDAQ:CTMX) and Its Rivals

CytomX Therapeutics (NASDAQ: CTMX) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare CytomX Therapeutics to related companies based on the strength of its earnings, risk, profitability, institutional ownership, dividends, valuation and analyst recommendations.

Earnings & Valuation

This table compares CytomX Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CytomX Therapeutics $15.04 million -$58.90 million -16.03
CytomX Therapeutics Competitors $290.27 million $35.99 million 56.05

CytomX Therapeutics’ peers have higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CytomX Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics 1 2 8 0 2.64
CytomX Therapeutics Competitors 1134 3426 11925 240 2.67

CytomX Therapeutics presently has a consensus target price of $33.88, suggesting a potential upside of 34.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.67%. Given CytomX Therapeutics’ peers stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares CytomX Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytomX Therapeutics -113.64% -92.42% -20.70%
CytomX Therapeutics Competitors -5,443.85% -164.39% -36.43%

Insider & Institutional Ownership

63.1% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.7% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CytomX Therapeutics peers beat CytomX Therapeutics on 7 of the 12 factors compared.

About CytomX Therapeutics

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply